Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 A pulse at the heart of targeted therapy.

Literature DB >> 19219016

A pulse at the heart of targeted therapy.

James E Bradner.

Abstract

Mesh：

Substances：

Year: 2009 PMID： 19219016 DOI： 10.1038/nchembio0309-144

Source DB: PubMed Journal: Nat Chem Biol ISSN： 1552-4450 Impact factor: 15.040

× No keyword cloud information.

11 in total

1. A quantitative analysis of kinase inhibitor selectivity.

Authors: Mazen W Karaman; Sanna Herrgard; Daniel K Treiber; Paul Gallant; Corey E Atteridge; Brian T Campbell; Katrina W Chan; Pietro Ciceri; Mindy I Davis; Philip T Edeen; Raffaella Faraoni; Mark Floyd; Jeremy P Hunt; Daniel J Lockhart; Zdravko V Milanov; Michael J Morrison; Gabriel Pallares; Hitesh K Patel; Stephanie Pritchard; Lisa M Wodicka; Patrick P Zarrinkar
Journal: Nat Biotechnol Date: 2008-01 Impact factor: 54.908

2. Dasatinib (BMS-354825) pharmacokinetics and pharmacodynamic biomarkers in animal models predict optimal clinical exposure.

Authors: Feng R Luo; Zheng Yang; Amy Camuso; Richard Smykla; Kelly McGlinchey; Krista Fager; Christine Flefleh; Stephen Castaneda; Ivan Inigo; David Kan; Mei-Li Wen; Robert Kramer; Anne Blackwood-Chirchir; Francis Y Lee
Journal: Clin Cancer Res Date: 2006-12-01 Impact factor: 12.531

3. Sole BCR-ABL inhibition is insufficient to eliminate all myeloproliferative disorder cell populations.

Authors: S Wong; J McLaughlin; D Cheng; C Zhang; K M Shokat; O N Witte
Journal: Proc Natl Acad Sci U S A Date: 2004-10-25 Impact factor: 11.205

4. Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized phase 2 trial.

Authors: Hagop Kantarjian; Ricardo Pasquini; Nelson Hamerschlak; Philippe Rousselot; Jerzy Holowiecki; Saengsuree Jootar; Tadeusz Robak; Nina Khoroshko; Tamas Masszi; Aleksander Skotnicki; Andrzej Hellmann; Andrey Zaritsky; Anatoly Golenkov; Jerald Radich; Timothy Hughes; Athena Countouriotis; Neil Shah
Journal: Blood Date: 2007-02-22 Impact factor: 22.113

5. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia.

Authors: B J Druker; M Talpaz; D J Resta; B Peng; E Buchdunger; J M Ford; N B Lydon; H Kantarjian; R Capdeville; S Ohno-Jones; C L Sawyers
Journal: N Engl J Med Date: 2001-04-05 Impact factor: 91.245

6. Cytokine-induced signaling networks prioritize dynamic range over signal strength.

Authors: Kevin A Janes; H Christian Reinhardt; Michael B Yaffe
Journal: Cell Date: 2008-10-17 Impact factor: 41.582

7. High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia.

Authors: Hagop Kantarjian; Moshe Talpaz; Susan O'Brien; Guillermo Garcia-Manero; Srdan Verstovsek; Francis Giles; Mary Beth Rios; Jianqin Shan; Laurie Letvak; Deborah Thomas; Stefan Faderl; Alessandra Ferrajoli; Jorge Cortes
Journal: Blood Date: 2003-12-24 Impact factor: 22.113

8. Cancer. Addiction to oncogenes--the Achilles heal of cancer.

Authors: I Bernard Weinstein
Journal: Science Date: 2002-07-05 Impact factor: 47.728

9. Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia.

Authors: Neil P Shah; Hagop M Kantarjian; Dong-Wook Kim; Delphine Réa; Pedro E Dorlhiac-Llacer; Jorge H Milone; Jorge Vela-Ojeda; Richard T Silver; H Jean Khoury; Aude Charbonnier; Nina Khoroshko; Ronald L Paquette; Michael Deininger; Robert H Collins; Irma Otero; Timothy Hughes; Eric Bleickardt; Lewis Strauss; Stephen Francis; Andreas Hochhaus
Journal: J Clin Oncol Date: 2008-06-09 Impact factor: 44.544

10. Clinical pharmacodynamics of high-dose methotrexate in acute lymphocytic leukemia. Identification of a relation between concentration and effect.

Authors: W E Evans; W R Crom; M Abromowitch; R Dodge; A T Look; W P Bowman; S L George; C H Pui
Journal: N Engl J Med Date: 1986-02-20 Impact factor: 91.245

1 in total

1. Lyn regulates creatine uptake in an imatinib-resistant CML cell line.

Authors: Denis O Okumu; Lucas J Aponte-Collazo; Brian J Dewar; Nathan J Cox; Michael P East; Katherine Tech; Ian M McDonald; Andrey P Tikunov; Ekhson Holmuhamedov; Jeffrey M Macdonald; Lee M Graves
Journal: Biochim Biophys Acta Gen Subj Date: 2019-12-24 Impact factor: 3.770

1 in total